Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
- PMID: 32871558
- DOI: 10.6004/jnccn.2020.7610
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic
Abstract
Hematopoietic growth factors, including erythrocyte stimulating agents (ESAs), granulocyte colony-stimulating factors, and thrombopoietin mimetics, can mitigate anemia, neutropenia, and thrombocytopenia resulting from chemotherapy for the treatment of cancer. In the context of pandemic SARS-CoV-2 infection, patients with cancer have been identified as a group at high risk of morbidity and mortality from this infection. Our subcommittee of the NCCN Hematopoietic Growth Factors Panel convened a voluntary group to review the potential value of expanded use of such growth factors in the current high-risk environment. Although recommendations are available on the NCCN website in the COVID-19 Resources Section (https://www.nccn.org/covid-19/), these suggestions are provided without substantial context or reference. Herein we review the rationale and data underlying the suggested alterations to the use of hematopoietic growth factors for patients with cancer in the COVID-19 era.
Similar articles
-
Hematologic Growth Factors.2016 Aug 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Aug 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644052 Free Books & Documents. Review.
-
Human hematopoietic growth factors: old lessons and new perspectives.Anticancer Res. 2000 Nov-Dec;20(6D):5155-64. Anticancer Res. 2000. PMID: 11326688 Review.
-
[Hematopoietic growth factors. Possibilities and limitations].Internist (Berl). 2010 Jul;51(7):863-71; quiz 872-3. doi: 10.1007/s00108-010-2641-2. Internist (Berl). 2010. PMID: 20544173 German.
-
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.Onkologie. 2002 Feb;25(1):32-9. doi: 10.1159/000055200. Onkologie. 2002. PMID: 11893881
-
Hematopoietic growth factors in cancer chemotherapy.Cancer Chemother Biol Response Modif. 1999;18:250-67. Cancer Chemother Biol Response Modif. 1999. PMID: 10800487 Review.
Cited by
-
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF).Support Care Cancer. 2022 Sep;30(9):7067-7077. doi: 10.1007/s00520-022-07103-5. Support Care Cancer. 2022. PMID: 35739328 Free PMC article. No abstract available.
-
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.Haematologica. 2022 Jun 1;107(6):1243-1263. doi: 10.3324/haematol.2021.279512. Haematologica. 2022. PMID: 35642485 Free PMC article.
-
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?Oncologist. 2022 Aug 5;27(8):625-636. doi: 10.1093/oncolo/oyac074. Oncologist. 2022. PMID: 35552754 Free PMC article. Review.
-
[G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer : Guidelines on supportive treatment part 1].Urologe A. 2022 May;61(5):537-551. doi: 10.1007/s00120-022-01831-6. Epub 2022 Apr 27. Urologe A. 2022. PMID: 35476110 Free PMC article. German.
-
COVID 19 and febrile neutropenia: Case report and systematic review.Travel Med Infect Dis. 2022 May-Jun;47:102305. doi: 10.1016/j.tmaid.2022.102305. Epub 2022 Mar 7. Travel Med Infect Dis. 2022. PMID: 35272019 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Miscellaneous
